

Hong Kong Exchanges and Clearing Limited take no responsibility for the representation as to its accuracy or completeness whatsoever for any loss howsoever arising out of or in connection with any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT

**HEPARIN SODIUM ACTIVE PHARMACEUTICAL INGREDIENT
AND ENOXAPARIN SODIUM ACTIVE PHARMACEUTICAL
INGREDIENT, OBTAINS APPROVAL FROM INDIA**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”), together with its subsidiaries referred to as the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Heparin Sodium Active Pharmaceutical Ingredient (the “**API**”) and Enoxaparin Sodium API of the Group has been approved by the Central Drugs Standard Control Organisation, Ministry of Health & Family Welfare of India for sales in the market.

DETAILS OF THE LICENSE

- (I) Product: Heparin Sodium API and Enoxaparin Sodium API
- (II) Validity period of the license: until January 23, 2025

The heparin sodium API product is made from purified heparin sodium from crude heparin isolated from porcine intestinal mucosa. Our heparin sodium API products are mainly used in the production of heparin sodium preparations and low molecular weight heparin APIs.

Enoxaparin sodium API is a sodium salt of depolymerized heparin obtained by chemically cleaving longer heparin chains into shorter chains by depolymerization of basic heparin benzyl esters. Heparin Sodium API is the main raw material for our Enoxaparin Sodium API. Enoxaparin Sodium API is used in the manufacture of Enoxaparin Sodium formulations.

BENEFITS AND IMPACTS TO THE COMPANY

The board of directors believes that India has a population of 1.39 billion, and is one of the important markets worldwide for heparin sodium and enoxaparin sodium APIs. With this approval in India, the Group will have access to the Indian market and is ready to provide high-quality and competitively priced heparin sodium and enoxaparin sodium API series products for Indian doctors and patients. Meanwhile, the successful registration of the Group's Heparin Sodium API and Enoxaparin Sodium API in India will facilitate and boost our sales of API in India and further accelerate the expansion of the Group's API business on a global scale.

Announcement is hereby given.

By order of the Board
Shenzhen Heralink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
March 15, 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.